KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Common Equity (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Common Equity for 15 consecutive years, with $114.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 94.37% year-over-year to $114.8 million, compared with a TTM value of $114.8 million through Dec 2025, up 94.37%, and an annual FY2025 reading of $114.8 million, up 94.37% over the prior year.
  • Common Equity was $114.8 million for Q4 2025 at Travere Therapeutics, up from $73.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $362.7 million in Q1 2021 and bottomed at -$30.5 million in Q3 2024.
  • Average Common Equity over 5 years is $148.5 million, with a median of $115.7 million recorded in 2023.
  • The sharpest move saw Common Equity surged 368.62% in 2023, then crashed 110.89% in 2024.
  • Year by year, Common Equity stood at $302.1 million in 2021, then crashed by 85.82% to $42.9 million in 2022, then skyrocketed by 368.62% to $200.8 million in 2023, then tumbled by 70.58% to $59.1 million in 2024, then skyrocketed by 94.37% to $114.8 million in 2025.
  • Business Quant data shows Common Equity for TVTX at $114.8 million in Q4 2025, $73.6 million in Q3 2025, and $32.7 million in Q2 2025.